Cancers & treatments·Regimen libraryConsolidation

High-dose melphalan and autologous stem-cell transplant

Checked 2026-09-09

Transplant-eligible myeloma after induction

One cycle

single day × 1

1-day cycle × 1 (tandem in selected high-risk patients)Intravenous

Components

Drug	Dose	Route	Days	Note
Melphalan Alkylating agent (nitrogen mustard)	200 mg/m² (140 mg/m² if over 70 or renal impairment)	IV	D1	day -2 or -1; stem cells reinfused day 0

Cycles

1 (tandem in selected high-risk patients)

1-day cycle

Emetogenicity

High (>90%)

G-CSF

Built into the protocol

Notes

Followed by lenalidomide 10 mg maintenance (with daratumumab in PERSEUS) until progression.

Used in

Multiple myeloma

Products

Melphalan (including hepatic delivery system)

Source

IFM 2009, NEJM 2017

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.